Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic fever. The virus is endemic in over 120 countries, causing over 350 million infections per year.
Dengue vaccine development is challenging because of the need to induce simultaneous protection against four antigenically distinct DENV serotypes and evidence that, under some conditions, vaccination can enhance disease due to specific immunity to the virus. While several live-attenuated tetravalent dengue virus vaccines display partial efficacy, it has been challenging to induce balanced protective immunity to all 4 serotypes. Instead of using whole-virus formulations, we are exploring the potentials for a particulate subunit vaccine, based on DENV E-protein displayed on nanoparticles that have been precisely molded using Particle Replication in Non-wetting Template (PRINT) technology.
Here we describe immunization studies with a DENV2-nanoparticle vaccine candidate. The ectodomain of DENV2-E protein was expressed as a secreted recombinant protein (sRecE), purified and adsorbed to poly (lactic-co-glycolic acid) (PLGA) nanoparticles of different sizes and shape. We show that PRINT nanoparticle adsorbed sRecE without any adjuvant induces higher IgG titers and a more potent DENV2-specific neutralizing antibody response compared to the soluble sRecE protein alone. Antigen trafficking indicate that PRINT nanoparticle display of sRecE prolongs the bio-availability of the antigen in the draining lymph nodes by creating an antigen depot. Our results demonstrate that PRINT nanoparticles are a promising platform for delivering subunit vaccines against flaviviruses such as dengue and Zika.
Dengue virus (DENV) is transmitted by mosquitoes and is endemic in over 120 countries, causing over 350 million infections yearly. Most infections are clinically unapparent, but under specific conditions, dengue can cause severe and lethal disease. DENV has 4 distinct serotypes and secondary DENV infections are associated with hemorrhagic fever and dengue shock syndrome. This enhancement of infection complicates vaccine development and makes it necessary to induce protective immunity against all 4 serotypes. Since whole virus vaccine candidates struggle to induce protective immunity, we are developing a nanoparticle display vaccine approach. We have expressed, purified and characterized a soluble recombinant E-protein (sRecE). Regardless of nanoparticle shape or size, particulation of sRecE enhances DENV specific IgG titers and induces a robust, long lasting neutralizing antibody response and by adsorbing sRecE to the nanoparticles, we prolong the exposure of sRecE to the immune system.
Nanoparticle display shows great promise in dengue vaccine development and possibly other mosquito-borne viruses like zika virus.
The Latest on: Nanoparticle vaccines
via Google News
The Latest on: Nanoparticle vaccines
- Emergex to drive vaccine development with R&D facility and new hire on February 19, 2019 at 2:30 am
A nanotechnology expert, Dr Williams has extensive experience in the field of gold nanoparticle development and has been ... "We are looking forward to working together to effectively progress our vac... […]
- mRNA Vaccines & Therapeutics market detailed in new research report on February 18, 2019 at 2:02 am
This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activit... […]
- Emergex Secures State-of-the-Art R&D Facility and Hires a Chief Scientific Officer to Drive Development of Its Vaccines on February 18, 2019 at 1:00 am
This gives the Company overall internal control of all its vaccine development programs. Furthermore, key personnel at the site, who are highly experienced in the design, production and development of ... […]
- Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 on February 12, 2019 at 1:21 pm
It is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology. “The... […]
- HIV glycans and nanoparticle vaccines on February 7, 2019 at 1:37 pm
Synthetic nanoparticles have attracted widespread interest for vaccine design, but how the immune system generates a response to multimeric nanoparticles remains unclear. Tokatlian et al. studied immu... […]
- A sweeter approach to vaccine design on February 7, 2019 at 12:07 pm
Engineering of nanoparticles with a dense array of glycans enables recognition by MBL, facilitating transport to the B cell zone and increasing the magnitude and quality of the humoral immune response ... […]
- The Race Is On: What mRNA Product Will Reach the Market First? on February 7, 2019 at 9:00 am
Encapsulation through packaging in lipid nanoparticles (LNPs) is currently the method of ... These factors heavily influence the availability of therapeutic proteins or vaccines. It is important for v... […]
- Sen. Blumenthal pushes for universal flu vaccine on February 1, 2019 at 3:05 am
"But a universal flu vaccine would be effective against all the strains and ... There are a lot of approaches they are taking, one involves nanoparticles, one involves DNA. They're not there yet, but ... […]
- Polymeric Nanoparticles for Tumor Vaccines on January 15, 2019 at 4:00 pm
Vaccines are complex preparations of proteins and other materials designed to produce maximal immune response to those proteins. One factor that determines a vaccine's potency is the ability of this m... […]
via Bing News